Research programme: monoclonal antibodies and antibody-drug conjugates - Intellect Neurosciences

Drug Profile

Research programme: monoclonal antibodies and antibody-drug conjugates - Intellect Neurosciences

Alternative Names: 1A10; 82E1; Anti-Aβ monoclonal antibodies; Caspase-cleaved tau antibody; IN-N01; IN-N01-OX2; N01-OX2; T01-OX2; TauC3 monoclonal antibody; TOC-1

Latest Information Update: 30 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immuno-Biological Laboratories; Northwestern University
  • Developer Intellect Neurosciences
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Amyloid inhibitors; Antioxidants; Protein aggregation inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Alzheimer's disease; Glaucoma

Most Recent Events

  • 15 Jun 2017 MRC Technology is now called LifeArc
  • 07 Jan 2016 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Intellect Neurosciences
  • 26 Oct 2015 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top